http://www.acc.org/Feed?clinicalTopicID=4ea474ce-5bda-4828-b03f-e99d73bea0c5 Clinical Topic Feed: Interventions and Structural Heart Disease en /Latest-in-Cardiology/Articles/2026/09/15/18/42/CMS-Finalizes-Updated-TAVR-National-Coverage-Determination The Centers for Medicare and Medicaid Services (CMS) has finalized updates to the National Coverage Determination (NCD) for transcatheter aortic valve replacement (TAVR), introducing significant changes to Medicare coverage requirements for patients with aortic stenosis. 1789571880000 Articles and Stories /Latest-in-Cardiology/Articles/2026/09/11/18/54/ACC-STS-and-SCAI-Issue-Joint-Statement-on-TAVR-National-Coverage-Determination The American College of Cardiology (ACC), Society of Thoracic Surgeons (STS) and Society for Cardiovascular Angiography & Interventions (SCAI) released the following joint statement on the transcatheter aortic valve replacement (TAVR) national coverage determination finalized by the Centers for Medicare and Medicaid Services (CMS). 1789153980000 Articles and Stories /Latest-in-Cardiology/Articles/2026/09/09/13/47/eagles-eye-view-09sep2026 In this week’s View, Dr. Eagle looks at some of the important trials presented at this year’s European Society of Cardiology (ESC) Congress. 1788961680000 Articles and Stories /Latest-in-Cardiology/Articles/2026/09/01/01/JACC-in-a-Flash Featured topics and Editors' Picks from all of ACC's JACC Journals. 1788264600000 Articles and Stories /Latest-in-Cardiology/Articles/2026/09/01/01/Journal-Wrap The hottest research from various peer-reviewed journals – handpicked weekly by the ACC. 1788264540000 Articles and Stories /Latest-in-Cardiology/Articles/2026/08/29/08/48/sun-545am-combo-tavi-esc-2026 Three late-breaking trials presented at ESC Congress 2026 offer new insights into the management of structural heart disease and heart failure (HF), spanning coronary revascularization during TAVI, transcatheter treatment of tricuspid regurgitation, and post-TAVI antithrombotic therapy. Together, the TAVI PCI, ACASA-TAVI and TRIC-I-HF studies provide important evidence to help refine treatment strategies and improve patient outcomes. 1788091440000 Articles and Stories /Latest-in-Cardiology/Articles/2026/08/24/12/30/sat-jacc-journals-esc-2026 Several abstracts and e-posters presented at ESC Congress 2026 and simultaneously published across the JACC family of journals highlight the expanding role of precision medicine, novel therapeutics, and advanced risk stratification across cardiovascular care. 1788002340000 Articles and Stories /Latest-in-Cardiology/Articles/2026/08/24/12/30/fri-reboot-paradox-esc-2026 Despite premature termination limiting the precision of mortality estimates, the REBOOT-PARADOX trial offers rare randomized, long-term patient-level data examining whether TAVR adds a survival benefit compared with optimal medical therapy (OMT) in symptomatic patients with paradoxical low-flow, low-gradient aortic stenosis (pLFLG). 1787928180000 Articles and Stories /Latest-in-Cardiology/Journal-Scans/2026/08/03/10/06/PARTNER-3 Both TAVR and SAVR were associated with a sustained, substantial improvement in patient-reported health status among patients with severe aortic stenosis (AS) considered at low risk, according to the seven-year outcomes of the PARTNER 3 trial published July 29 in JACC. 1785862800000 Articles and Stories /Latest-in-Cardiology/Articles/2026/07/15/17/40/ACC-SCAI-and-STS-Submit-Feedback-on-Proposed-TAVR-NCD The ACC, along with the Society for Cardiovascular Angiography & Interventions (SCAI) and the Society of Thoracic Surgeons (STS), submitted formal comments to the Centers for Medicare and Medicaid Services (CMS) on July 15 regarding the proposed decision memo for the National Coverage Determination (NCD) for TAVR. 1784138100000 Articles and Stories